LLLiteng Lin

Liteng Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liteng Lin has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Kangshun Zhu

    Laboratory of Interventional Radiology, Department of Minimally Invasive Interventional Radiology and Interventional Cancer Center, Guangdong Engineering Technology Research Center of Interventional Oncology and Precision Drug Delivery, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China

    11 shared publications
  • Mingyue Cai

    Laboratory of Interventional Radiology, Department of Minimally Invasive Interventional Radiology and Interventional Cancer Center, Guangdong Engineering Technology Research Center of Interventional Oncology and Precision Drug Delivery, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China

    6 shared publications
  • Wensou Huang

    Laboratory of Interventional Radiology, Department of Minimally Invasive Interventional Radiology and Interventional Cancer Center, Guangdong Engineering Technology Research Center of Interventional Oncology and Precision Drug Delivery, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China

    6 shared publications
  • Jianxin Liu

    Laboratory of Interventional Radiology, Department of Minimally Invasive Interventional Radiology and Interventional Cancer Center, Guangdong Engineering Technology Research Center of Interventional Oncology and Precision Drug Delivery, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China

    5 shared publications
  • Jingjun Huang

    Laboratory of Interventional Radiology, Department of Minimally Invasive Interventional Radiology and Interventional Cancer Center, Guangdong Engineering Technology Research Center of Interventional Oncology and Precision Drug Delivery, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China

    5 shared publications
  • Licong Liang

    Laboratory of Interventional Radiology, Department of Minimally Invasive Interventional Radiology and Department of Radiology, The Second Affiliated Hospital, Guangzhou Medical University, Changgangdong Road, Haizhu District, Guangzhou, Guangdong Province 510261, China

    5 shared publications

Latest Publications

  • Open Access

    SIRT or TACE in combination with lenvatinib and PD-(L)1 inhibitor in high-tumor burden hepatocellular carcinoma: a multicenter, retrospective, propensity score-matched study

    by Jingjun Huang, Huimin Niu, Hui Zhang, Mingyue Cai, Zhiheng Wang, Yongjian Guo, Licong Liang, Liteng Lin, Tingqi Yang, Jiabai Huang, et al.

    Background: The combination of transarterial chemoembolization (TACE), lenvatinib, and PD-(L)1 inhibitors (TACE-L-P) has shown improved outcomes in hepatocellular carcinoma (HCC). This study aims to compare the efficacy and safety of selective internal radiation therapy (SIRT) plus lenvatinib and PD-(L)1 inhibitors (SIRT-L-P) versus TACE-L-P in Chinese HCC patients with high-tumor burden. Materials and Methods: This retrospective, multicenter, propensity score-matched study included HCC patients, beyond up-to-seven criteria or with portal vein tumor thrombus, treated with SIRT-L-P or TACE-L-P across four Chinese centers (2022–2024). Study endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety. Results: A total of 234 patients were included (109 in SIRT-L-P, 125 in TACE-L-P). After matching, 91 patients per group remained with well-balanced baseline characteristics. SIRT-L-P demonstrated significantly improved median PFS (12.1 vs. 9.0 months; HR 0.647, P = 0.021), OS (2-year OS rate 68.9% vs. 39.1%; HR 0.517, P = 0.014), and ORR (78.0% vs. 61.5% by mRECIST, P = 0.017; 56.0% vs. 35.2% by RECIST 1.1, P = 0.005) compared to TACE-L-P. Safety outcomes showed a lower overall incidence of adverse events (AEs) in the SIRT-L-P group compared to TACE-L-P (any grade: 83.5% vs. 95.6%, P = 0.008), while grade 3 AE rates were not significantly different (24.2% vs. 30.8%, P = 0.319). In a subset of patients receiving SIRT-L-P, risk tier combining post-SIRT neutrophil–lymphocyte ratio and peripheral CD8+ T-cell proportion was an independent predictor for PFS and OS. Conclusion: This study provides the first real-world evidence indicating that SIRT-L-P significantly improves efficacy and safety compared to TACE-L-P in high-tumor burden HCC.


  • Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC

    by Rui Li, Jianxin Liu, Feilong Ye, Siqin He, Jingjun Huang, Mengdan Zhou, Qifeng Xie, Zhile Liu, Wei Cheng, Guodong Wang, et al.


  • Open Access

    Acid-responsive engineered bacteria with aberrant In-Situ anti-PD-1 expression for post-ablation immunotherapy of hepatocellular carcinoma

    by Yue Li, Xiaobin Wang, Feilong Ye, Xiaoyang Hong, Ye Chen, Jiabai Huang, Jianxin Liu, Xinkun Huang, Licong Liang, Yongjian Guo, et al.


  • Open Access

    Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal Hypertension

    by Rui Li, Zhile Liu, Wensou Huang, Yongjian Guo, Chan Xie, Hongmei Wu, Jianxin Liu, Xiaoyang Hong, Xiaobin Wang, Jingjun Huang, et al.


  • Open Access

    Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study

    by Mingyue Cai, Licong Liang, Jian Zhang, Nianping Chen, Wensou Huang, Yongjian Guo, Xiaotao Hong, Liteng Lin, Yaohong Liu, Cao Dan, et al.

    Background: The management of hepatocellular carcinoma (HCC) with high tumor burden and major portal vein tumor thrombosis (PVTT) remains a great challenge. The authors aimed to investigate the efficacy and safety of lenvatinib plus drug-eluting bead transarterial chemoembolization (DEB-TACE) and hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil and leucovorin (Len+DEB-TACE+HAIC) versus lenvatinib plus DEB-TACE (Len+DEB-TACE) for HCC greater than 7.0 cm accompanied with major PVTT. Materials and methods: This multicenter retrospective cohort study evaluated consecutive patients with HCC (> 7.0 cm) and major PVTT who received Len+DEB-TACE+HAIC (Len+DEB-TACE+HAIC group) or Len+DEB-TACE (Len+DEB-TACE group) between July 2019 and June 2021 from eight institutions in China. Objective response rate (ORR), time to progression (TTP), overall survival (OS), and treatment-related adverse events (TRAEs) were compared between the two groups by propensity score matching (PSM). Results: A total of 205 patients were included. After PSM, 85-paired patients remained in the study cohorts. Patients in the Len+DEB-TACE+HAIC group had higher ORR (61.2% vs. 34.1%, P < 0.001), longer TTP (median, 9.8 vs. 5.9 months, P < 0.001), and prolonged OS (median, 16.7 vs. 12.5 months, P < 0.001) than those in the Len+DEB-TACE group. The ORR and TTP of both intrahepatic tumor (ORR: 64.7% vs. 36.5%, P < 0.001; median TTP: 10.7 vs. 7.0 months, P < 0.001) and PVTT (ORR: 74.1% vs. 47.1%, P < 0.001; median TTP: 17.4 vs. 7.6 months, P < 0.001) were better in the Len+DEB-TACE+HAIC group than the Len+DEB-TACE group. The frequency of grade 3-4 TRAEs in the Len+DEB-TACE+HAIC group were comparable to those in the Len+DEB-TACE group (38.8% vs. 34.1%, P = 0.524). Conclusion: The addition of HAIC to Len+DEB-TACE significantly improved ORR, TTP, and OS over Len+DEB-TACE with an acceptable safety profile for large HCC with major PVTT.


  • Open Access

    Mechanisms and therapeutic strategies to combat the recurrence and progression of hepatocellular carcinoma after thermal ablation

    by Feilong Ye, Lulu Xie, Licong Liang, Zhimei Zhou, Siqin He, Rui Li, Liteng Lin, Kangshun Zhu

    Thermal ablation (TA), including radiofrequency ablation (RFA) and microwave ablation (MWA), has become the main treatment for early-stage hepatocellular carcinoma (HCC) due to advantages such as safety and minimal invasiveness. However, HCC is prone to local recurrence, with more aggressive malignancies after TA closely related to TA-induced changes in epithelial-mesenchymal transition (EMT) and remodeling of the tumor microenvironment (TME). According to many studies, various components of the TME undergo complex changes after TA, such as the recruitment of innate and adaptive immune cells, the release of tumor-associated antigens (TAAs) and various cytokines, the formation of a hypoxic microenvironment, and tumor angiogenesis. Changes in the TME after TA can partly enhance the anti-tumor immune response; however, this response is weak to kill the tumor completely. Certain components of the TME can induce an immunosuppressive microenvironment through complex interactions, leading to tumor recurrence and progression. How the TME is remodeled after TA and the mechanism by which the TME promotes HCC recurrence and progression are unclear. Thus, in this review, we focused on these issues to highlight potentially effective strategies for reducing and preventing the recurrence and progression of HCC after TA.


  • Open Access

    HBV suppresses macrophage immune responses by impairing the TCA cycle through the induction of CS/PDHC hyperacetylation

    by Jiaxin Bei, Ye Chen, Qianbing Zhang, Xiaobin Wang, Liteng Lin, Jingjun Huang, Wensou Huang, Mingyue Cai, Weiguo Cai, Yongjian Guo, et al.

    Background: It is now understood that HBV can induce innate and adaptive immune response disorders by affecting immunosuppressive macrophages, resulting in chronic HBV infection. However, the underlying mechanism is not fully understood. Dysregulated protein acetylation can reportedly influence the differentiation and functions of innate immune cells by coordinating metabolic signaling. This study aims to assess whether HBV suppresses macrophage-mediated innate immune responses by affecting protein acetylation and to elucidate the underlying mechanisms of HBV immune escape. Methods: We investigated the effect of HBV on the acetylation levels of human THP-1 macrophages and identified potential targets of acetylation that play a role in glucose metabolism. Metabolic and immune phenotypes of macrophages were analyzed using metabolomic and flow cytometry techniques. Western blot, immunoprecipitation, and immunofluorescence were performed to measure the interactions between deacetylase and acetylated targets. Chronic HBV persistent infected mice were established to evaluate the role of activating the tricarboxylic acid (TCA) cycle in macrophages for HBV clearance. Results: Citrate synthase/pyruvate dehydrogenase complex hyperacetylation in macrophages after HBV stimulation inhibited their enzymatic activities and was associated with impaired TCA cycle and M2-like polarization. HBV downregulated Sirtuin 3 (SIRT3) expression in macrophages by means of the toll-like receptor 2 (TLR2)-NF-κB- peroxisome proliferatoractivated receptor γ coactivator 1α (PGC-1α) axis, resulting in citrate synthase/pyruvate dehydrogenase complex hyperacetylation. In vivo administration of the TCA cycle agonist dichloroacetate inhibited macrophage M2-like polarization and effectively reduced the number of serum HBV DNA copies. Conclusions: HBV-induced citrate synthase/pyruvate dehydrogenase complex hyperacetylation negatively modulates the innate immune response by impairing the TCA cycle of macrophages. This mechanism represents a potential therapeutic target for controlling HBV infection.


  • Open Access

    T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma

    by Xiaobin Wang, Qiaoyun Zhang, Jingwen Zhou, Zecong Xiao, Jianxin Liu, Shaohui Deng, Xiaoyang Hong, Wensou Huang, Mingyue Cai, Yongjian Guo, et al.

    Background Immune checkpoint blockade (ICB) monotherapy provides poor survival benefit in hepatocellular carcinoma (HCC) due to ICB resistance caused by immunosuppressive tumor microenvironment (TME) and drug discontinuation resulting from immune-related side effects. Thus, novel strategies that can simultaneously reshape immunosuppressive TME and ameliorate side effects are urgently needed. Methods Both in vitro and orthotopic HCC models were used to explore and demonstrate the new role of a conventional, clinically used drug, tadalafil (TA), in conquering immunosuppressive TME. In detail, the effect of TA on M2 polarization and polyamine metabolism in tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) was identified. After making clear the aforementioned immune regulatory effect of TA, we introduced a nanomedicine-based strategy of tumor-targeted drug delivery to make better use of TA to reverse immunosuppressive TME and overcome ICB resistance for HCC immunotherapy. A dual pH-sensitive nanodrug simultaneously carrying both TA and programmed cell death receptor 1 antibody (aPD-1) was developed, and its ability for tumor-targeted drug delivery and TME-responsive drug release was evaluated in an orthotopic HCC model. Finally, the immune regulatory effect, antitumor therapeutic effect, as well as side effects of our nanodrug combining both TA and aPD-1 were analyzed. Results TA exerted a new role in conquering immunosuppressive TME by inhibiting M2 polarization and polyamine metabolism in TAMs and MDSCs. A dual pH-sensitive nanodrug was successfully synthesized to simultaneously carry both TA and aPD-1. On one hand, the nanodrug realized tumor-targeted drug delivery by binding to circulating programmed cell death receptor 1-positive T cells and following their infiltration into tumor. On the other hand, the nanodrug facilitated efficient intratumoral drug release in acidic TME, releasing aPD-1 for ICB and leaving TA-encapsulated nanodrug to dually regulate TAMs and MDSCs. By virtue of the combined application of TA and aPD-1, as well as the efficient tumor-targeted drug delivery, our nanodrug effectively inhibited M2 polarization and polyamine metabolism in TAMs and MDSCs to conquer immunosuppressive TME, which contributed to remarkable ICB therapeutic efficacy with minimal side effects in HCC. Conclusions Our novel tumor-targeted nanodrug expands the application of TA in tumor therapy and holds great potential to break the logjam of ICB-based HCC immunotherapy.


  • Open Access

    Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma

    by Lulu Xie, Mingyu Liu, Mingyue Cai, Wensou Huang, Yongjian Guo, Licong Liang, Weiguo Cai, Jianxin Liu, Wei Liang, Yitong Tan, et al.


  • Open Access

    Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases

    by Mingyu Liu, Lulu Xie, Yuying Zhang, Jianning Chen, Xiang Zhang, Ye Chen, Wensou Huang, Mingyue Cai, Licong Liang, Miaoling Lai, et al.

    Hepatocellular carcinoma (HCC) with lung metastasis is associated with poor prognosis and poor therapeutic outcomes. Studies have demonstrated that stiffened stroma can promote metastasis in various tumors. However, how the lung mechanical microenvironment favors circulating tumor cells remains unclear in metastatic HCC. Here, we found that the expression of cell migration-inducing hyaluronan-binding protein (CEMIP) was closely associated with lung metastasis and can promote pre-metastatic niche formation by increasing lung matrix stiffness. Furthermore, upregulated serum CEMIP was indicative of lung fibrotic changes severity in patients with HCC lung metastasis. By directly targeting CEMIP, pirfenidone can inhibit CEMIP/TGF-β1/Smad signaling pathway and reduce lung metastases stiffening, demonstrating promising antitumor activity. Pirfenidone in combination with sorafenib can more effectively suppress the incidence of lung metastasis compared with sorafenib alone. This study is the first attempt to modulate the mechanical microenvironment for HCC therapy and highlights CEMIP as a potential target for the prevention and treatment of HCC lung metastasis.